Cargando…
P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
Autores principales: | Jaccard, A., Bridoux, F., Roeloffzen, W., Minnema, M. C., Bergantim, R., Hájek, R., João, C., Cibeira, M. T., Palladini, G., Schönland, S., Merlini, G., Milani, P., Dimopoulos, M. A., Ravichandran, S., Hegenbart, U., Agis, H., Gros, B., Asra, A., Dergarabetian, E., Magarotto, V., Leonidakis, A., Cheliotis, G., Sonneveld, P., Wechalekar, A., Kastritis, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429565/ http://dx.doi.org/10.1097/01.HS9.0000849712.10352.58 |
Ejemplares similares
-
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023) -
P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022) -
S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023) -
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018) -
The century of revolution, 1603-1714 /
por: Hill, Christopher, 1912-2003
Publicado: (1982)